Popular Prescription Weight Loss Drugs Linked to Uncommon Blinding Condition

A study led by Mass Eye and Ear found a higher risk of a rare blinding eye condition called NAION in patients prescribed semaglutide (Ozempic or Wegovy) for diabetes or weight loss compared to those not taking these drugs. Patients with diabetes on semaglutide were over four times more likely to develop NAION, while overweight or obese patients were over seven times more likely. The study, published in JAMA Ophthalmology, analyzed over 17,000 patients and highlighted the importance of discussing NAION as a potential risk with patients considering these drugs. Although the study does not establish causality, it suggests a significant association that warrants further investigation in a larger and more diverse population. The researchers noted limitations in the study population and the need for future studies to explore the underlying reasons for this link. The findings emphasize the importance of informed discussions between patients and healthcare providers, especially for those with existing optic nerve issues.